Aqualung Therapeutics is an early-stage biotech company that is committed to finding novel targets in the treatment of respiratory diseases. Their team is highly skilled at clinical development and they are working collaboratively with the FDA to ensure both acute and chronic respiratory diseases that have significant unmet medical need receive priority review. The company strategies include the deployment of a humanized monoclonal antibody (ALT-100) which targets a novel inflammatory mediator eNAMPT, enabling medical practitioners to address the unmet need for novel, effective therapies for VILI, IPF, and pulmonary hypertension in patients. Aqualung Therapeutics (ALT) is developing multi-pronged strategies to address the development of severe lung inflammation which is essential to the severity and outcomes of acute and chronic lung disorders such as acute lung injury, ventilator-induced lung injury (VILI), idiopathic pulmonary fibrosis, and pulmonary hypertension.